While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
Dr. Reddy's will present the safety profile of the phase 2 study, and interim data of the phase 3 study, which is expected to complete by 2pt February 2021.
The jump in profit is due to the better performance of the API business.
The company continued to maintain clear FDA status across its plants and has received 12 ANDA approvals during 9MFY21
Jubilant announced the completion of demerger of pharma and LSI business into two separate companies
The company posted net profit of Rs.7.61 crores for the period ended December 31, 2019.
The company posted net loss of Rs. 55.51 crores for the period ended December 31, 2019.
The company posted net profit of Rs.62.17 crores for the period ended December 31, 2019.
The company posted net profit of Rs.203.38 crores for the period ended December 31, 2019.
The company's business in India geography posted strong growth during the quarter as it grew by 20% on a y-o-y basis and registered revenues of Rs. 1,643 crore.
Subscribe To Our Newsletter & Stay Updated
